US-based life sciences investment firm VenBio Partners has closed its Global Strategic Fund II at $315m following anchor investments from pharmaceutical companies Amgen, Merck and Baxalta.

The fund, which had a target size of $250m, also attracted money from other, unnamed limited partners.

VenBio Strategic Fund II will be led by Robert Adelman and Corey Goodman, both managing directors at the firm. They will be supported by managing partner Behzad Aghazadeh and new additions Aaron Royston, who has been appointed…